Compared to laboratory animals, humans are extremely heterogeneous with respect to the many factors that can influence the distribution and biological effects of toxic chemicals. This heterogeneity can prevent an accurate assessment of the impact of a particular toxic compound on the health of an individual subject. Some of the factors that can significantly modify the host response to certain drugs, which serve in this review as a model for environmental chemicals, are enumerated and discussed. Although the mechanisms by which many of these factors modify the biological effects of certain environmental chemicals and drugs have been determined in some cases, better definition of the nature of interactions between these factors and environmental chemicals in a particular individual is required at a biochemical and molecular level. Recommendations are offered for the further development of our knowledge concerning interactions between environmental chemicals and such factors in a particular individual. 
This background document considers certain aspects of the impact of environmental chemicals on the development of disease and injury in man. The primary focus is the role played by certain key variables in determining how humans respond to environmental chemicals and drugs. Since result of chronic exposure to potentially toxic chemicals in the environment of our modern industrial cities is difficult. Effects and interactions of various potentially toxic chemicals in the environment are difficult to assess because both the chemical nature as well as the concentration of many of these environmental compounds remain to be defined precisely. For these reasons, various drugs, administered alone or in combination, will have to serve temporarily, at least, as models of how other environmental chemicals might act and interact in different individuals to produce toxicity and how certain genetic and environmental factors could modify their effects in man.
The virtue of using drugs as a model of how potentially toxic chemicals might act in man is that the chemical nature, the dose, and the route of administration of the drug can be clearly defined and the individual himself used as a control, so that relatively minor effects of various genetic and environmental factors on drug disposition can be examined.
However, the utilization of drugs as a model does not by any means obviate all methodological problems. The main problem in the use of man as a subject to define environmental and genetic vari-ables affecting drug disposition is that man himself is exceedingly heterogeneous with repect to many genetic and environmental factors. Each human being, except for persons who are one of a set of identical twins or triplets, is unique with respect to many environmental and genetic factors that could influence drug disposition. Therefore, most studies on the role of these factors in determining drug disposition have had to be performed in experimental animals where the laboratory conditions with respect to the environment and genetic background of the animal can be most closely defined and held investigation, may appear impressive at first glance, the precise quantitative definition of the role of each factor in determining drug disposition and the mechanisms by which each factor operates to alter drug disposition have not yet been satisfactorily elucidated in most cases. Nevertheless, the division of variables shown in Table 1 into those affecting the external environment of laboratory animals, those operating on their internal environment and those determining the pharmacokinetic and pharmacodynamic aspects by which a drug is administered may prove useful. From what we now know of how drugs enter, pass through, and are eliminated by an organism, we can categorize certain possible mechanisms by which chemicals and drugs act and interact to produce toxicity. Table 2 identifies discrete biochemical processes and sites responsible for the disposition of drugs introduced into an organism; the variables in the external and internal environment listed in Table 1 can act to alter the disposition of a drug or toxic chemical in an organism at these sites. The same dose of a certain drug given by the same route to patients of the same age and sex, suffering from the same disease, may produce toxicity in some, the desired therapeutic effect in others and no effect whatever in still others. Physicians have come to recognize that in practice drugs rarely behave as ideally as they are described in most pharmacology texts and that drugs frequently do not exhibit the therapeutic effects hoped for when they are prescribed. Paul Dudley White estimated this disappointing result to have occurred in more than half his patients. The basis for the discrepancy between anticipated and actual responses to drugs lies in the immense variation among subjects. Thus, an inquiry seems warranted into the precise nature of this interindividual variation, which had previously been ill defined and dismissed with the vague term "biological variation". The same wide range of effect has been observed in the toxicity of certain chemicals, such as carbon tetrachloride or strychnine in laboratory animals (2) . Figure 1 shows three types of curves, each describing a genetically distinct mode of inherited variation encountered clinically when the same dose of a given drug is administered by the same route to a group of patients or normal volunteers, and a particular quantitative response to a drug is measured. This measurement could be the concentration of the drug or of its metabolites in biological fluids or the change produced by the drug in the patient's pulse rate, blood pressure, or activity of a particular enzyme.
The simplest curve describing variation is the unimodal, Gaussian curve (type A in Fig. 1) (3) , but its single-humped, deceptively simple curve is the most difficult to interpret. The first interpretation of the unimodal distribution curve is genetic similarity of the population tested with respect to the genes controlling the particular response being measured.
For example, each of the subjects investigated may have the same genetically-determined blood group or the same activity of a specific drug-metabolizing enzyme, such as plasma pseudocholinesterase, the enzyme responsible for biotransformation of succinylcholine. Table 3 , approximately one person in 2500 has a double dose of the gene for atypical plasma pseudocholinesterase and hence is susceptible to the possibility of prolonged apnea after succinylcholine administration. Although most of the other conditions listed in Table 3 are rare, they have not been extensively sought and may occur more frequently in certain populations. A major contribution of pharmacogenetics is to alert physicians to the possibility that several unusual drug reactions are inherited and will thus develop in some relatives of affected persons after administration of the offending therapeutic agents. In this connection, half of the siblings and half of the children of anyone who has inherited the dominantly-transmitted gene causing the rare, but frequently fatal, malignant hyperthermia with muscular rigidity will also exhibit a similar aberrant response during anesthesia with the agents listed in Table 3 . Therapy of malignant hyperthermia with intravenous procaine or procainamide has been reported to produce dramatic relief of fever and rigidity. Table 3 have been divided into those involving defective drug metabolism and those involving defective interaction of the drug with tissues, thereby producing abnormal pharmacological responses.
Genetic Variations in Drug Clearance
A major cause of adverse reactions is drug accumulation of toxic concentrations in certain persons who, for various reasons, are unable to eliminate normal doses of a therapeutic agent as fast as most others. Large variations in the rates at which healthy, nonmedicated volunteers clear antipyrine (4), bishydroxycoumarin (5) , and phenylbutazone (6) from their plasma were reported 20 years ago from Brodie's laboratory. More recently, large differences have also been shown among normal subjects in the plasma concentrations of chlorpromazine, propranolol, warfarin, phenytoin, or procainamide after a standard dose of any one of these drugs. Formerly, it was assumed that if a given drug were administered to a population in the same dose and by the same route, all subjects would have similar blood and receptor site concentrations of the drug, and hence that all subjects would respond similarly to the therapeutic agent. In the light of these large individual differences in rates of elimination of many drugs, the principle of wide variations in the disposition of and responsiveness to therapeutic agents is now being proclaimed. This principle of pharmacological individuality has long been appreciated by practicing physicians.
Mechanisms of Variation
The mechanism responsible for large individual variations in plasma half-lives of several commonly used drugs was recently elucidated by the application of an old technique. The twin method, introduced by Sir Francis Galton in 1875, estimates the relative contribution of environmental and genetic factors in producing a particular trait. The method, based on a comparison for any given trait of the intratwin differences for identical and fraternal twins, assumes environmental equality. twin study of the rate of production of the major halothane metabolite (10) and a twin study on the major metabolite of nortriptyline (11) .
Family studies of drug elimination may be less satisfactory than twin studies for two reasons, the first being that the disposition of certain therapeutic agents changes with age and varies according to sex. Twin studies are by definition age-corrected, but the results of family studies are difficult to interpret because of the difficulty in correcting for this poorly defined change in drug disposition with age. Secondly, rates of drug metabolism have been altered either in laboratory animals or in man by such environmental constituents as caffeine, nicotine, 3-methylcholanthrene, 3-4-benzpyrene, and various insecticides. Therefore, the closer environmental similarity of children as compared to parents could be partially responsible for changes in drug-metabolizing capacity observed in family studies. The influence exerted by numerous environmental constituents on drug-metabolizing capacity may explain why, in one family study, a correlation was found between healthy, nonmedicated husbands and wives in their plasma half-lives of phenylbutazone.
Environmental Factors and Genetic Control of Their Expression
The genetic control of large variations among healthy, nonmedicated volunteers in rates of drug elimination has several potentially useful implications. In the first place, since rates of drug elimination are genetically, rather than environmentally, controlled in healthy, nonmedicated subjects, they should be highly reproducible, stable values. This expectation has been verified for several different drugs.
Secondly, determination of drug-metabolizing capacity in an individual might be ascertained before chronic drug administration as a guide to adjusting dosage according to individual requirements, thereby helping to reduce frequent occurrences of toxicity or undertreatment encountered when the same dose of a drug is given to all subjects. One Table 4 .
Over the past several years, interest has focused on a wide variety of environmental factors that can affect rates of drug elimination in human subjects. Because rates of drug elimination in human subjects exhibit large interindividual variations and are influenced by so many different factors, studies designed to identify specific factors must be carefully controlled in order to exclude a host of variables that could exert influence while selecting and quantitating only a single factor as an independent variable. Without adequately controlling many of the factors listed in Table 1 , what appears initially to be an effect of a single factor could eventually prove to be a product of many interacting or associated factors. The task of partitioning large interindividual variations in drug elimination of exceedingly heterogeneous populations into component parts is complicated because some seemingly pure "environmental" factors such as smoking and diet are closely associated with other environmental as well as with genetic characteristics.
In 1969 a technique was introduced to overcome this major difficulty of adequately controlling human studies on factors that affect rates of drug elimination (12) . This approach depended on the use of each subject as his own control (12) . Antipyrine was measured in an apparently basal state. Then a single condition in the volunteer's environment was changed, such as the institution of chronic drug administration, and antipyrine pharmacokinetic measurements were repeated during and after the period of chronic drug administration. The quantitative differences between the pharmacokinetic values obtained prior to and after chronic drug administration or some other test condition indicated to what extent the chronic drug administration or the other test condition affected hepatic antipyrine metabolism. Several precautions and assumptions had to be taken. It was necessary to determine the apparent volumes of distribution (aVd) of antipyrine in both the basal and perturbed states since a change in aVd, rather than in hepatic metabolism, could produce altered values for antipyrine half-life or metabolic clearance rates. The decay of antipyrine in plasma had to be shown to be proportional to the rate of production of the major antipyrine metabolite, 4-OH antipyrine, if decay of antipyrine in plasma was to be acceptable as a measure of its metabolism. This relationship, suggested in 1950 by the work of Brodie and Axelrod (4) on the metabolic conversion in man of antipyrine to 4-OH antipyrine, has recently been confirmed in other laboratories (13, 14) . this relationship for antipyrine and Figure 3 reveals that it applies as well for aminopyrine, another test drug that is now being used (13) (14) (15) (16) an individual is in a truly basal, uninduced or uninhibited, state can never be complete; it is partially attainable through repeated measurements of the rate of elimination of a particular drug, and through a careful history of exposures at work and at home to compounds or conditions. (Table 5) .
Although a disease process may alter the pharmacokinetic parameters of a given drug in an individual by only 20%o, this negligible change can be clinically significant for a potent drug with a low therapeutic index. Such small changes in rates of drug elimination may require compensation by appropriate alterations in dose.
Determination of plasma antipyrine half-lives as a convenient, simple test of assessing rates for hepatic antipyrine metabolism (17) , and its further refinement permits each individual to serve as his own control in investigating effects of drugs, environmental chemicals or other conditions on hepatic antipyrine metabolism (12) . With this test, studies have been undertaken to measure the relative contributions of a number of different factors, 16 .5% longer in older than in younger subjects (19) ; a poor correlation existed between age and antipyrine half-life (r = -0.25) (19) . Although changes in rates of drug metabolism with age are small compared with much larger interindividual variations of sex and age in matched normal volunteers under basal conditions, the effect of age alone on drug disposition depends on the particular drug under study. Thus, disposition of some drugs such as aminopyrine exhibit greater change with age than does antipyrine, whereas with others such as ethanol it does not change at all. Significant alterations in drug disposition occur over very much shorter periods, both circadian and seasonal changes in rates of drug disposition having been recorded. We observed that in some normal male volunteers the half-lives of both phenacetin and acetaminophen are approximately 15% shorter at 2:00 p.m. than at 6:00 a.m. (Fig. 4) (20) .
Our own studies (21) , as well as those of others (22) , revealed that chronic ethanol ingestion increased the metabolism of drugs in some, but not all, subjects. And cigarette smoking altered phenacetin metabolism (23, 24) and accelerated antipyrine metabolism (25) . On an isocaloric diet, alterations of the carbohydrate to protein ratio changed antipyrine and theophylline metabolism (26) . Low protein was associated with retarded metabolism of these drugs (26) . Nevertheless, in obese subjects starvation for 7 to 10 days failed to alter antipyrine or tolbutamide metabolism (27) . Occupational exposure to certain environmental chemicals, such as DDT, accelerated metabolism of phenylbutazone and cortisol (28) , as well as of antipyrine (29) . Thus some environmental factors affecting drug disposition in experimental animals ( (30) , less so in adulthood (19) and least in old age (19) . Clearly other factors must be involved. One commonly encountered environmental chemical, the birth control pill, inhibits hepatic drug metabolism (31, 32) , but age as a factor in the observed decrease in rates of drug metabolism of this chemical can be excluded for several reasons, among them that the main age effects are observed in the pediatric and geriatric groups and that decreased drug elimination occurs with age in groups composed entirely of males.
Effects of Disease on Drug Metabolism
Only recently was abnormal drug metabolism demonstrated convincingly to accompany various disease states. This association remained unproven so long because of the contrasting problems of investigating disease states in laboratory animals and human beings. In experimental animals the effect of disease states on drug disposition can be carefully measured because the environmental and genetic characteristics can be determined and controlled rigorously; several such disease states in which appropriate studies on animals showed that drug disposition was altered are listed in Table 1 . Development of a highly reproducible model in the animal permitted precise quantitation of the effects on drug disposition produced by a specific pathologic lesion of known intensity and severity, and made possible a comparison with drug elimination under normal basal conditions in the same animal.
By contrast, in human disease each patient represents an almost unique constellation of genetic and environmental variables. Thus, variation in drug disposition due to these factors is immense. Furthermore, a very broad spectrum exists in the severity, intensity, and duration of most human disease; large changes in the disease process and its effects occur commonly with time, even when only a single organ is affected. Generally, however, several organs are simultaneously involved. The functional status of the cardiovascular, endocrine, hepatic, hormonal, and nervous systems fluctuates during many disease processes that produce time fluctuations in drug disposition. In Effects of disease states on the rate of absorption of the drug depend on many factors including the site of drug administration. If the drug is administered orally, the influence of disease on rates of drug absorption will depend on the nature of the disease process, whether it affects the areas in the gut where the drug is normally absorbed, how the disease alters the normal physiologic volume, pH, temperature, viscosity, surface tension and composition of the gastrointestinal secretions and contents (33) . Rates of drug absorption may also be influenced by whether or not food is present, the nature and quantity of bile salts and bacterial flora, the rate of splanchnic blood flow, prior diet and food intake as well as gastrointestinal motility (33) . Until recently little was known about how disease states altered these factors in man; however, large interindividual differences in rates of absorption of many orally administered drugs occur in hospital patients (34) (35) (36) as well as in normal volunteers (37) (38) (39) . For example, a 7-fold range in the amount of tetracycline absorbed was reported in six fasting, healthy subjects (40) . Variations in gastric emptying may contribute significantly to large interindividual differences in drug absorption rate because numerous physiologic conditions, such as posture and autonomic activity, as well as the temperature, volume, viscosity and tonicity of gastric contents, can change gastric emptying time. Grossly impaired absorption of paracetamol occurs in patients with delayed gastric emptying and pyloric stenosis (41) . In patients with slow gastric emptying L-dopa may be ineffective (42) . Therapeutic failure of orally administered drugs usually accompanies gastric stasis (41, 43, 44) . In patients with achlorhydria, aspirin was absorbed significantly faster, and plasma salicylate concentrations were higher than in controls (Fig. 5) (44) . Prescott (45) reported the interesting observation that acetaminophen plasma concentrations were significantly higher after oral administration in 12 convalescent hospital patients in bed than in seven healthy ambulant volunteers matched for age and sex. Since rates of absorption of orally administered pills and capsules are dependent on rates of their dissolution and dispersion, some of the factors enumerated above can alter such rates, thereby contributing to variations in drug absorption. It is interesting and somewhat surprising that the absorption of p-aminosalicylic acid and insoniazid was unchanged by gastrectomy performed for peptic ulcer, although complete failure of ethionamide absorption occurred in some patients (46) . Furthermore, gastrectomy failed to alter the absorption of sulfisoxazole, quinidine or ethambutol unless vagotomy had been performed, thereby slowing gastric emptying (47) .
In jejunal disease folic acid absorption is diminished (48) . In ileal disease the transport of bile acids may be impaired, as well as the enterohepatic transport of many lipid soluble drugs, since bile acids promote the gastrointestinal absorption of fat and certain fat soluble compounds including many drugs and vitamins A, D, K, and E. Ileal disease may be associated with impaired B12 absorption, since B12 is absorbed in the ileum after it forms a complex with intrinsic factor produced by the gastric parietal cell. Defective function of the ileum secondary to surgical removal or disease through interference with B12 absorption can lead to pernicious anemia. B12 absorption can also be impaired in gastric diseases where parietal cell function is abnormal, producing intrinsic factor deficiency and pernicious anemia. In some patients with pernicious anemia precipitating or blocking antibodies to intrinsic factor have been identified (49, 50) . In addition, regional enteritis as well as tropical sprue, celiac disease, and Whipple's disease can produce B12 malabsorption. In steatorrhea, fat-soluble drugs and vitamins may be lost in the feces, producing deficiency of the fat-soluble vitamins, a deficiency of vitamin D being by far the most significant chronic problem in gastrointestinal disease.
Some active drugs are produced after metabolism of the inactive form by gut bacteria, the best example being cleavage of salicylazosulfapyridine, the drug of choice in the treatment of chronic ulcerative colitis. Diseases or drugs that change the nature of the gastrointestinal flora can affect the disposition of other drugs metabolized by gut bacteria. Possibly the effect of large doses of charcoal on gastrointestinal absorption of phenacetin is mediated by gut bacteria and induction of AHH activity in these bacteria by charcoal (51) . The absorption of digoxin is reduced by neomycin administration (52) .
The binding of many drugs to albumin is altered in several disease states. For example, the phenytoin binding was decreased in plasma of 15 uremic patients (53) . The size of the unbound fraction correlated well with blood urea nitrogen, serum creatinine and clinical state of the patient. In addition to phenytoin, other organic acids including congo red, sulfonamides, thyroxine, tryptophan, clofibrate, fluorescein, and methyl red exhibited decreased protein binding in uremia. By contrast, most organic bases bind normally to plasma from uremic patients. A clinically significant neutral compound, digitoxin, exhibited decreased plasma binding in uremic patients (54) . Disease states including cirrhosis and nephritis are associated with hypoproteinemia and hypoalbuminemia. In both these conditions the unbound fraction of most drugs is elevated compared to the unbound fraction that exists with normal protein and albumin concentrations. These situations illustrate the danger of selecting drug dose solely on the basis of total drug concentrations in plasma, rather than on the free concentration, since only the free form is pharmacologically active. In cirrhosis, the plasma binding of the organic bases quinidine, diazepam and triamterene, as well as of the organic acid fluorescein are all decreased.
Since poor renal function is associated with decreased excretion of several drugs, it is important to modify normal drug dosage in uremic patients. Methods for this have been presented by Dettli and others (55) (56) (57) (58) . Dettli (57) described a linear relationship between the overall elimination rate constant ke and the endogenous creatinine clearance (Vcr'):
where knr is the mean extrarenal elimination rate constant in anuric patients and 8 is a constant relating Ver' to the renal elimination rate constant kr of the drug. This equation can be used for about 40 drugs; simple nomograms have been devised which allow the estimation of the rate of drug elimination in the patient with kidney disease from the value of Vcr' (57, 59). However, there are numerous drugs whose apparent elimination rates are unaltered by uremia, including tolbutamide, phenobarbital, histamine, phenacetin, phenytoin, antipyrine, quinidine, propranolol, and vitamin D (53) .
Much less study has been devoted to effects of disease states on receptor sites and the kinetics of formation and dissociation of drug receptor complexes. Comparison of the basal state of receptors under normal and disease conditions should facilitate analysis of drug action. Advances in receptor isolation by techniques such as affinity labeling now permit careful in vitro studies to assess how diseases affect receptors. For example, such techniques have the potential of revealing whether cholinergic receptors from mysasthenic skeletal muscle function normally in response to transmitter and in the kinetics of drug binding and dissociation. Diseases can also alter the local environment of receptors and change their conformation. A classic example of how environmental conditions alter the binding of a drug to its receptor is that of digoxin with receptors in cardiac muscle, where the efficacy of the drug in producing inotropic and chronotropic effects can be appreciably altered by changes in potassium ion concentration or pH near the receptor.
Effect of Fever on Drug Disposition
In the course of many diseases, fever, a concomitant of many diseases, develops either acutely or chronically. Yet, until recently, the effects of fever on drug distribution were unexamined. In 1975, it was shown that etiocholanolone-induced fever in normal volunteers was associated with the prolongation of plasma antipyrine half-life in 11 of 14 volunteers who developed fever (60) (Fig. 6) (62) (Fig. 7) . These observations were confirmed in 1974 (63) and were extended in 1975 (64) (Fig. 8) (66) showed that the metabolic pathway for the hepatic biotransformation of prednisone was affected by liver disease and that the extent of this effect depended on the nature and severity of the disease. In 1972 Faigle (67) reported that in patients with severe bilharziasis, metabolism of the schistosomacide niridazole (nitrothiamidazol) was impaired, as revealed by higher blood levels of the drug and a higher incidence of adverse effects than in normal subjects. In 1973 Branch et al. (68) reported that serum antipyrine half-life was prolonged in patients with liver disease, an observation confirmed in 1974 by Andreasen et al. (69) and by Andreasen and Vesell (70) (Fig. 9) . Also in 1974, hrs.
Hepner and Vesell (15) (14) .
Further studies utilizing patients with various hepatic disorders disclosed that the ABT differentiated different types of hepatic dysfunction (71) (Fig. 10) . For example, in 16 of 21 subjects with cholestasis not caused by malignant disease, the mean 14CO2 excretion was normal. The mean percentage of administered 14C excreted in 14CO2 in 2 hr in control patients was 7.1 + 1.3 (SD)% and significantly less (p < 0.01) in patients with portal cirrhosis (2.6 ± 1.2%), fatty liver (4.7 + 1.1%), hepatitis (2.6 ± 1.4%), and hepatic malignancy (3.5 + 1.8%) (71) (Fig. 10) .
It is now firmly established that hepatocellular disease is associated with decreased capacity to metabolize some drugs. However, it has not yet been determined whether the extent of depression of hepatic drug-metabolizing function in an individual with liver disease is similar for all drugs biotransformed by the liver.
Our observations that rates of aminopyrine elimination are reduced in almost all patients with parenchymal liver disease and observations by Branch (68) and Andreasen (69, 70) (76) . No inherent incompatibility exists between failure to correlate rates of drug metabolism in the basal state and high correlation of these rates when the hepatic drug-metabolizing system is induced or inhibited. One explanation for this is the heterogeneity, both qualitative and quantitative, of cytochrome P-450, each of the multiple forms probably acting on different drug substrates (77 . . 17 .6hrs.
14.4 t=s.
rate of antipyrine metabolism was produced by phenobarbital for all subjects in the study, even though in some it changed more than in others to attain this rate (12) . These observations are compatible with and help explain lack of significant correlations among rates of elimination of some drugs in the basal, unmedicated state, but significant correlation in the induced state of drug metabolism. X: 20 10 59 of such correlations and the misconceptions concerning their clinical applicability. The principal aim of such correlations among rates of elimination of different drugs in the same subject is to predict in a given patient the behavior of one drug as against another. The predictive value is not equivalent to the correlation coefficient, as implied in so many recent studies, but rather to the square of the correlation coefficient. In clinical practice, the usefulness of predictive values of less than 90% is limited; to achieve a predictive value of 90%, the correlation coefficient must be 0.95. With lower correlation coefficients, the difference between the predictive value and the correlation coefficient is larger. For example, a correlation coefficient of 0.80 has a predictive value of 0.64; and a correlation coefficient of 0.60 has a predictive value of 0.36, so that in only 1 of 3 patients would a prediction based on such a relationship be accurate. It must be stressed that a low p value does not necessarily indicate that the correlation is biologically significant or clinically useful. The p value does not provide information on the biologic significance of a relationship, but rather on the probability of reproducing the best line that can be drawn through as many of the data points as possible. Thus, a correlation coefficient of 0. 30 Figure 11 . Trimodality was later firmly established by appropriate family studies that demonstrated autosomal recessive inheritance of interindividual differences in the rates of isoniazid acetylation. However, the distribution curves for antipyrine and nortriptyline are less clear from the few individuals shown in Figure 11 . While the distribution of antipyrine half-lives in the plasma of 14 concerning the role played by certain key variables in determining how humans respond to environmental chemicals and drugs has identified several future needs and directions of inquiry.
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In order to define the impact of various potentially toxic chemicals in the environment on human populations, it is necessary to estimate more accurately the specific concentrations of various toxic chemicals in different geographical areas and under different working conditions, as well as to determine whether such potentially toxic compounds actually are present in human biological fluids and tissues.
The normal mechanisms by which these toxic compounds are handled must be better defined in man and here, too, the need for better knowledge of how to extrapolate from animal studies to man is obvious.
Improvements in methodology are required at various levels: (a) The further development of chemical analytical methods and kinetic techniques for the recognition of trace amounts of chemicals as well as for the development of substitute surrogate or model compounds where it would be unethical to study highly toxic compounds in man; (b) the application of more refined genetic analyses to polygenic systems; (c) the development of methcds to identify the discrete components of polygenic systems by laboratory techniques; (d) the use of in vitro techniques (including tissue culture) to predict the response of individuals to drugs or compounds in the environment.
The study of population genetics in order to: (a) identify particular populations at high risk because of their possession of certain alleles in high frequency and (b) to elucidate ethnic variability in the metabolism of or response to drugs and toxic compounds.
The pathophysiological mechanisms underlying proven associations between polymorphism and disease, especially those produced or enhanced by drugs, must be elucidated.
Genetic factors should be looked for when attempts are made to unravel the mechanisms of clinically significant drug interactions.
It is critical to develop adequate animal models to study the problems of human exposure to toxic chemicals. We need to define better how far we can safely extrapolate data from laboratory animals to man if laboratory animals are to serve as satisfactory models for the issues we are addressing.
In searching for genetic factors that cause interindividual differences in response to environmental chemicals and drugs, there is a need to measure rates of production of the major metabolites of a toxic compound or drug, rather than the rate of disappearance of the parent chemical.
